News >

Expanded Access Data Confirm Safety, Efficacy of Ruxolitinib in Myelofibrosis

Published: Friday, Dec 16, 2016

Lynda Foltz, MD

Lynda Foltz, MD

Worldwide clinical experience with the JAK1/2 inhibitor ruxolitinib (Jakafi) in patients with myelofibrosis has yielded safety and efficacy data similar to results of a pivotal randomized trial, a review of data from an expanded access program showed.1

1. Foltz L, Paulmbo GA, Martino B, et al. Safety and efficacu of ruxolitinib for the final enrollment of JUMP: an open-label, multicenter, single-arm expanded-access study in patients with myelofibrosis. Presented at: 58th ASH Annual Meeting and Exposition; December 2-6, 2016; San Diego, CA. Abstract 3107.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication